Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002139 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

A Phase 1 study of HIV Infections and Bacterial Infections, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00002139: Completed Phase 1 study of HIV Infections and Bacterial Infections, sponsored by Pfizer.

NCT00002139 is a Phase 1 study of HIV Infections and Bacterial Infections that has completed, run by Pfizer. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002139, a Phase 1 study of HIV Infections and Bacterial Infections, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

Conditions Studied

HIV Infections Bacterial Infections

Interventions

  • DRUG Azithromycin

Study Locations (1)

Kansas

  • Ctr for Phase I Research - Wichita

Trial Details

FieldValue
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT00002139 record still lists

NCT00002139 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.

NCT00002139 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT00002139 about?

NCT00002139 is a clinical study titled "Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.". To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

What is the current status of trial NCT00002139?

This trial is currently completed. It is a Phase 1 study.

What conditions does trial NCT00002139 study?

This clinical trial studies the following conditions: HIV Infections, Bacterial Infections.

What interventions are being tested in trial NCT00002139?

The interventions under investigation include: Azithromycin (DRUG).

Who is sponsoring clinical trial NCT00002139?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002139 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002139, the US trial registry maintained by the National Library of Medicine. NCT00002139 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.